Class / Patent application number | Description | Number of patent applications / Date published |
514334000 | The six-membered hetero rings are bonded directly to each other | 33 |
20080275088 | Use of Collismycin and Derivatives Thereof as Oxidative Stress Inhibitors - The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease. | 11-06-2008 |
20080312284 | Amorphous Form of 1,2-Dihydropyridine Compound - An amorphous form of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridine-2-one. | 12-18-2008 |
20090062345 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS - The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, | 03-05-2009 |
20090076087 | DEUTERIUM-ENRICHED ETORICOXIB - The present application describes deuterium-enriched etoricoxib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20100035931 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS - The present invention is directed to tripyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved. | 02-11-2010 |
20100048635 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS - The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease. | 02-25-2010 |
20100099714 | AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases - The invention provides methods for treating, preventing, and delaying the onset of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, Pick's disease, and the like), dementia, mild cognitive impairments, glaucoma, ocular hypertension, and pain (e.g., neuropathic pain, headaches, and the like) by administering therapeutically effective amounts of AMPA receptor antagonists and NMDA receptor antagonists to patents in need thereof. The invention also provides combinations, kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists and NMDA receptor antagonists. Exemplary AMPA receptor antagonists include 1,2-dihydropyridine compounds, such as 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one. Exemplary NMDA receptor antagonists include adamantane compounds, such as memantine. | 04-22-2010 |
20100120862 | MONOCYCLIC COMPOUNDS AND THEIR USE AS TRPV1 LIGANDS - The invention relates to compounds of formula I | 05-13-2010 |
20100152243 | Treatment of renal cell carcinoma - Methods are provided of treating renal cancer by administration of certain 3,3′,4,4′-tetrahydroxy-2,2′-bipyridine-N,N′-dioxide compounds, especially 3,3′,4,4′-tetrahydroxy-2,2′-bipyridine-N,N′-dioxide (Orellanine), using particular administration protocols and dosing regimens, as well as pharmaceutical compositions suitable for use in the treatment methods that are provided. | 06-17-2010 |
20100168174 | Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain - The invention provides methods for treating and/or preventing neuropathic pain by administering to patients in need thereof therapeutically effective amounts of AMPA receptor antagonists; and cholinesterase inhibitors and/or anti-neuropathic pain agents. The neuropathic pain may be painful diabetic neuropathy. The invention also provides kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists; and cholinesterase inhibitors and/or anti-neuropathic pain agents. The AMPA receptor antagonists may be, for example, 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one. The cholinesterase inhibitor may be, for example, 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine (donepezil). | 07-01-2010 |
20100179193 | AMPA Receptor Antagonists and Zonisamide for Neuropathic Pain - The invention provides methods for treating and/or preventing neuropathic pain by administering to patients therapeutically effective amounts of AMPA receptor antagonists and zonisamide. The neuropathic pain may be diabetic neuropathy. The invention also provides kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists and zonisamide. The AMPA receptor antagonist may be, for example, 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-di-hydropyridin-2-one. | 07-15-2010 |
20100240704 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM - Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system. | 09-23-2010 |
20100317698 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them - Compounds of formula (I): | 12-16-2010 |
20110003859 | N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER - Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 01-06-2011 |
20110092544 | FUNGICIDAL PYRIDINES - Disclosed are compounds of Formula 1, N-oxides, and salts thereof, | 04-21-2011 |
20110118316 | Use of Quaternary Pyridinium Compounds for Vasoprotection and/or Hepatoprotection - The invention relates to a method for the treatment or prevention of diseases or conditions associated with vascular endothelium dysfunction or liver injury comprising the administration to a patient in a need of such treatment or prevention of a therapeutically or prophylactically effective amount of a compound selected from the group consisting of: | 05-19-2011 |
20110152324 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 06-23-2011 |
20110237627 | METHODS OF SYNTHESIZING ANATABINE - Anatabine is obtained by reacting benzophenoneimine with 3-aminomethyl pyridine to form benzylhydrylidene-pyridin-3-yl-methyl-amine. The benzylhydrylidene-pyridin-3-yl-methyl-amine is treated with a non-nucleophilic base and a dielectrophile, such as cis-1,4-dichloro-2-butene, followed by acidification, then basification, to provide anatabine. The resulting anatabine is substantially free from contaminants and displays good stability. In an alternative embodiment, the benzylhydrylidene-pyridin-3-yl-methyl-amine may be used in the synthesis of other alkaloids such as anabasine, nornicotine, N-methylanabasine, and anabaseine. | 09-29-2011 |
20110288129 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS - The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, | 11-24-2011 |
20120077846 | Treatment of renal cell carcinoma - Methods are provided of treating renal cancer by administration of certain 3,3′,4,4′-tetrahydroxy-2,2′-bipyridine-N,N′-dioxide compounds, especially 3,3′,4,4′-tetrahydroxy-2,2′-bipyridine-N,N′-dioxide (Orellanine), using particular administration protocols and dosing regimens, as well as pharmaceutical compositions suitable for use in the treatment methods that are provided. | 03-29-2012 |
20120122932 | Methods and Compositions for Controlling Ectoparasites - A method for inhibiting hatching of an ectoparasite egg, the method comprising exposing the ectoparasite egg to at least one metal chelating agent and/or metalloprotease inhibitor, wherein the metal chelating agent is a compound comprising at least two heteroatoms able to simultaneously coordinate with a metal ion, at least one of the two heteroatoms being selected from nitrogen, sulfur, oxygen and phosphorus, wherein the compound comprises at least one carbocyclic ring substituted with at least one heteroatom and/or with a substituent containing at least one heteroatom, or the compound comprises at least one heterocyclic ring containing at least one heteroatom, wherein said heterocyclic ring is optionally substituted with at least one heteroatom and/or with a substituent containing at least one heteroatom is provided. Methods of treating ectoparasite infestations and compositions for use in such methods are also provided. | 05-17-2012 |
20120172398 | CO-CRYSTALS OF TRAMADOL AND COXIBS - The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses in pharmaceutical formulations for the treatment of pain. | 07-05-2012 |
20120178782 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATIVE DISEASES - Synergistic pharmaceutical compositions and the methods for preventing and treating proliferative diseases such as cancer and psoriasis. The compositions comprise synergistic combinations of: (i) an acyl-CoA-synthetase enzyme inhibitor (AcsI4), (ii) a compound having an inhibiting effect on enzymes with cyclooxygenase activity (COX); and (iii) a compound selected from a 5-lypoxygenase enzyme (LOX-5) inhibitor and a leukotriene receptor antagonist. | 07-12-2012 |
20120196899 | METHODS AND PRODUCTS FOR TREATING INFLAMMATION - Pharmaceutical compositions comprising an isolated form of a compound of Formula IB (e.g., R-(+)-anatabine) or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low-level inflammation. Compounds of Formula I also can be provided, for example, in other vehicles such as beverage products and consumer products such as lotions and creams. | 08-02-2012 |
20120196900 | PYRIDINE NON-CLASSICAL CANNABINOID COMPOUNDS AND RELATED METHODS OF USE - Disclosed are compounds of the formula I: | 08-02-2012 |
20120232115 | PHARMACEUTICAL, DIETARY SUPPLEMENT, AND FOOD GRADE SALTS OF ANATABINE - Anatabine is obtained by reacting benzophenoneimine with 3-aminomethyl pyridine to form benzylhydrylidene-pyridin-3-yl-methyl-amine. The benzylhydrylidene-pyridin-3-yl-methyl-amine is treated with a non-nucleophilic base and a dielectrophile, such as cis-1,4-dichloro-2-butene, followed by acidification, then basification, to provide anatabine. The resulting anatabine is substantially free from contaminants and displays good stability. In an alternative embodiment, the benzylhydrylidene-pyridin-3-yl-methyl-amine may be used in the synthesis of other alkaloids such as anabasine, nornicotine, N-methylanabasine, and anabaseine. | 09-13-2012 |
20120245202 | METHODS AND PRODUCTS FOR TREATING INFLAMMATION - Pharmaceutical compositions comprising an isolated form of a compound of Formula I or IA (e.g., anatabine or S-(−)-anatabine) or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low-level inflammation. Compounds of Formula I also can be provided, for example, in other vehicles such as beverage products and consumer products such as lotions and creams. | 09-27-2012 |
20120322829 | USE OF A DIPYRIDYL COMPOUND FOR TREATING ROSACEA - A compound of formula (I) below: | 12-20-2012 |
20140057949 | Beverage Products - This disclosure provides beverage products comprising a compound of Formula I, such as anatabine, suitable for human consumption. | 02-27-2014 |
20140357670 | DIHYDROPYRIDINONE MGAT2 INHIBITORS - The present invention provides compounds of Formula (I): | 12-04-2014 |
20140371273 | POLYMORPHS OF PERAMPANEL - The present invention provides novel crystalline forms of perampanel, pharmaceutical compositions comprising same, methods for their preparation and uses thereof for treating seizures and epilepsy. | 12-18-2014 |
20160030407 | Method of Treating Inflammatory Lung Disease - Pharmaceutical compositions comprising an isolated form of a compound of Formula I or IA (e.g., anatabine or S-(−)-anatabine) or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low-level inflammation. Compounds of Formula I also can be provided, for example, in other vehicles such as beverage products and consumer products such as lotions and creams. | 02-04-2016 |
20160039759 | PROCESS FOR THE PREPARATION OF PERAMPANEL - The present invention relates to processes for the preparation of perampanel and its intermediates. | 02-11-2016 |